211 results on '"Vekeman, F."'
Search Results
2. Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A: PO-TU-147
3. PCN341 REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
4. COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING: CN4
5. Very Low Compliance for Vulvovaginal Atrophy (VVA) Treatment: A Retrospective U.S. Healthcare Claims Database Analysis
6. The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States
7. ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A RETROSPECTIVE CHART REVIEW STUDY AT THREE LARGE TERTIARY ONCOLOGY CENTERS IN THE UNITED STATES
8. MAINTENANCE OF WEIGHT LOSS OR STABLE WEIGHT IN SUBJECTS WITH OBESITY: A RETROSPECTIVE LONGITUDINAL ANALYSIS OF ELECTRONIC MEDICAL RECORD DATA
9. A Life-Course Assessment Of Medication Use And Medical Costs Of Lennox-Gastaut Syndrome (Lgs)
10. Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting
11. 2512 Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?
12. Adherence to Iron Chelation Therapy and associated Healthcare resource Utilization and costs in Medicaid Patients with Thalassemia
13. Kidney involvement in Tuberous Sclerosis Complex: the impact on Health Care resource use and costs in the Netherlands
14. Overall survival in post-menopausal women with hr+/her2- metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy
15. PIH32 - Very Low Compliance for Vulvovaginal Atrophy (VVA) Treatment: A Retrospective U.S. Healthcare Claims Database Analysis
16. Medical Complications And Resource Utilization In Blood Transfusion–Dependent Patients With Myelofibrosis By Iron Chelation Therapy Use
17. High Utilizers Of Health Care Resources: Results From The Multicenter Compact Study Of Complications In Patients With Sickle Cell Disease And Utilization Of Iron Chelation Therapy
18. High Cost Patients And Cost Patterns From Pediatric To Adult Care In A Medicaid Population With Sickle Cell Disease
19. PCN33 - Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting
20. PSY11 - MAINTENANCE OF WEIGHT LOSS OR STABLE WEIGHT IN SUBJECTS WITH OBESITY: A RETROSPECTIVE LONGITUDINAL ANALYSIS OF ELECTRONIC MEDICAL RECORD DATA
21. PSY24 - ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A RETROSPECTIVE CHART REVIEW STUDY AT THREE LARGE TERTIARY ONCOLOGY CENTERS IN THE UNITED STATES
22. PND51 - A Life-Course Assessment Of Medication Use And Medical Costs Of Lennox-Gastaut Syndrome (Lgs)
23. Pulse Pressure and Stroke Risk: Development and Validation of a Stroke Risk Equation
24. Health Care Resource Use and Direct Costs Associated with Fragile X Syndrome (FXS) in the United States
25. Development and validation of a new chronic kidney disease risk equation: the role of pulse pressure
26. Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD)
27. Incremental Cost Of Brain Metastases Among Patients With Metastatic Melanoma
28. Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders
29. Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the United States
30. PCV14 Are Vasodilators of Value in the Care of Patients Hospitalized for Acute Heart Failure?
31. PSY64 Development and Validation of a Classification Algorithm for Prophylactic Versus on-Demand Factor VIII Therapy in Patients With Hemophilia A
32. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty
33. 7133 POSTER Treatment (tx) Patterns and Toxicity of Angiogenesis Inhibitors in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) in Spain
34. 7162 POSTER A Pan-European Study of Treatment (trx) Patterns and Toxicity of Angiogenesis Inhibitors in Patients (pts) With Advanced Renal Cell Carcinoma (RCC)
35. Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).
36. Treatment (trx) of metastatic renal cell carcinoma (mRCC) with angiogenesis inhibitors (AIs): Safety and treatment patterns observed in Taiwanese patients.
37. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease
38. PCN2 SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED KINGDOM: PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY
39. 723 TREATMENT (TRX) PATTERNS AND TOXICITY OF ANGIOGENESIS INHIBITORS IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN UNITED KINGDOM (UK)
40. PSY43 - Kidney involvement in Tuberous Sclerosis Complex: the impact on Health Care resource use and costs in the Netherlands
41. PSY27 - Adherence to Iron Chelation Therapy and associated Healthcare resource Utilization and costs in Medicaid Patients with Thalassemia
42. PCN31 - Overall survival in post-menopausal women with hr+/her2- metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy
43. PCN49 COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB
44. PUK28 ASSESSMENT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT GUIDELINES CHANGES ON DOSING PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
45. PUK9 SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
46. PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
47. PSY35 PERSISTENCE AND COMPLIANCE OF DEFEROXAMINE VERSUS DEFERASIROX IN MEDICAID PATIENTS WITH SICKLE-CELL DISEASE (SCD)
48. Evaluation of Cardiac Comorbidities in Patients with Metastatic Breast Cancer Receiving Doxorubicin-Based and Non-Doxorubicin-Based Chemotherapy.
49. Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia
50. Comparison of epoetin alfa (EPO) and darbepoetin alfa (DARB) utilization in cancer chemotherapy patients treated in a hospital outpatient setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.